Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.64 |
| ▸ | GLP1R | P43220 | 4/20 | 0.61 |
| ▸ | GCGR | P47871 | 1/20 | 0.61 |
| ▸ | GIPR | P48546 | 1/20 | 0.61 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.60 |
| ▸ | CALCR | P30988 | 3/20 | 0.60 |
| ▸ | CCKBR | P32239 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 2/20 | 0.59 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.58 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.58 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182918 | 0.96 | TFPI (0.64) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL31182935 | 0.95 | TFPI (0.62) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL30120636 | 0.94 | TFPI (0.66) | TFPIGLP1RVIPR1BACE1BACE2 | |
| SCHEMBL30721553 | 0.93 | TFPI (0.66) | TFPIGLP1RVIPR1BACE1BACE2 | |
| SCHEMBL31683259 | 0.93 | TFPI (0.64) | TFPIVIPR1VIPR2 | |
| SCHEMBL29373682 | 0.92 | TFPI (0.68) | TFPIGLP1RVIPR1BACE1BACE2 | |
| SCHEMBL29811053 | 0.92 | IL23R (0.59) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL30721600 | 0.92 | TFPI (0.64) | TFPIGLP1RGCGRGIPRVIPR1 | |
| SCHEMBL31182868 | 0.92 | VIPR2 (0.61) | TFPIGLP1RVIPR1CALCRCCKBR | |
| SCHEMBL30436788 | 0.92 | TFPI (0.59) | TFPIGLP1RGCGRGIPRVIPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294433-A1 | IMMUNOGENIC COMPOSITION, USE AND METHODS | GlaxoSmithKline Biologicals SA (BE) | 2023-12-27 | — | — | EP | disclosed |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-02 | — | — | US | disclosed |
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-09-15 | — | — | US | disclosed |
| WO-2022175423-A1 | IMMUNOGENIC COMPOSITION, USE AND METHODS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-08-25 | — | — | WO | disclosed |
| EP-4010014-A1 | IMMUNOGENIC COMPOSITION | GlaxoSmithKline Biologicals S.A. (BE) | 2022-06-15 | — | — | EP | disclosed |
| EP-4009951-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GlaxoSmithKline Biologicals S.A. (BE) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | TFPI 1391/4885GLP1R 2107/4885GCGR 2388/4885 |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | TFPI 1391/4885GLP1R 2107/4885GCGR 2388/4885 |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | CXCL10, CCL2, CCL11 | TFPI 3568/4885GLP1R 2834/4885GCGR 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.